
NeuroPace (NPCE) Stock Forecast & Price Target
NeuroPace (NPCE) Analyst Ratings
Bulls say
NeuroPace Inc. has demonstrated a significant improvement in patients' quality of life through its RNS system for epilepsy, with a measurable increase of 3.2 points on the QOLIE-89 survey after one year of treatment. The company has also benefitted from favorable macro trends, evidenced by a growth in comprehensive epilepsy centers (CECs) from 151 in 2012 to 256 in 2019, alongside a 150% increase in epileptologists per capita, enhancing access to care. Additionally, NeuroPace recorded a notable revenue growth of 75.5% between 2022 and 2024, showcasing a positive inflection in its financial performance.
Bears say
NeuroPace Inc faces a challenging financial outlook characterized by a persistent history of significant net losses, with expectations to continue incurring losses in the near term, raising concerns about achieving or sustaining profitability. The company may require additional capital to fund its operations, which poses risks of unfavorable terms and potential cost-cutting measures that could further jeopardize its business. Existing financial obligations, including a restrictive term loan and uncertainties surrounding an expiring distribution agreement, add further complexity to the company's financial stability and stock performance.
This aggregate rating is based on analysts' research of NeuroPace and is not a guaranteed prediction by Public.com or investment advice.
NeuroPace (NPCE) Analyst Forecast & Price Prediction
Start investing in NeuroPace (NPCE)
Order type
Buy in
Order amount
Est. shares
0 shares